CRIS Current Research Information System

LUGARESI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.624
NA - Nord America 13.829
EU - Europa 9.412
SA - Sud America 1.370
Continente sconosciuto - Info sul continente non disponibili 1.157
AF - Africa 536
OC - Oceania 24
Totale 41.952
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.491
VN - Vietnam 5.027
SG - Singapore 3.670
CN - Cina 3.438
GB - Regno Unito 2.559
IT - Italia 2.306
DE - Germania 1.533
HK - Hong Kong 1.104
BR - Brasile 1.016
FR - Francia 788
IN - India 729
RU - Federazione Russa 561
BD - Bangladesh 500
SE - Svezia 363
IE - Irlanda 269
KR - Corea 265
ZA - Sudafrica 260
JP - Giappone 249
NL - Olanda 194
EE - Estonia 185
FI - Finlandia 153
CA - Canada 141
UA - Ucraina 136
AR - Argentina 129
ID - Indonesia 109
TR - Turchia 78
EC - Ecuador 73
TG - Togo 73
MX - Messico 68
AT - Austria 67
PH - Filippine 63
IQ - Iraq 58
CI - Costa d'Avorio 53
CO - Colombia 48
CH - Svizzera 43
ES - Italia 42
PL - Polonia 38
IR - Iran 36
PK - Pakistan 35
JO - Giordania 33
TH - Thailandia 31
UZ - Uzbekistan 31
GR - Grecia 30
JM - Giamaica 29
CL - Cile 28
SA - Arabia Saudita 28
SC - Seychelles 27
BE - Belgio 24
PY - Paraguay 24
BG - Bulgaria 23
VE - Venezuela 21
EG - Egitto 20
MY - Malesia 20
AU - Australia 19
CR - Costa Rica 18
KE - Kenya 16
MA - Marocco 16
HR - Croazia 15
NG - Nigeria 15
TW - Taiwan 15
DO - Repubblica Dominicana 14
DZ - Algeria 14
PE - Perù 14
AZ - Azerbaigian 13
KZ - Kazakistan 12
RO - Romania 12
GT - Guatemala 11
HN - Honduras 11
LB - Libano 11
UY - Uruguay 11
CZ - Repubblica Ceca 10
IL - Israele 10
NI - Nicaragua 10
NP - Nepal 10
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
RS - Serbia 8
LT - Lituania 7
PS - Palestinian Territory 7
AL - Albania 6
BO - Bolivia 6
GA - Gabon 6
PR - Porto Rico 6
PT - Portogallo 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
CY - Cipro 5
ET - Etiopia 5
GP - Guadalupe 5
BH - Bahrain 4
DK - Danimarca 4
GE - Georgia 4
NZ - Nuova Zelanda 4
OM - Oman 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BS - Bahamas 3
GH - Ghana 3
Totale 40.733
Salva come PNG Salva come JPEG
Città #
Singapore 2.394
Southend 2.332
Fairfield 1.400
Ho Chi Minh City 1.317
Ashburn 1.196
Hanoi 1.133
Hong Kong 1.063
Woodbridge 630
Seattle 607
Houston 605
Wilmington 599
Council Bluffs 580
Hefei 573
San Jose 551
Beijing 547
Princeton 532
Ann Arbor 504
Santa Clara 504
Cambridge 495
Boardman 441
Dong Ket 438
Lauterbourg 422
Chandler 349
Dublin 257
Nanjing 246
Bologna 243
Seoul 237
Westminster 234
Tokyo 230
Milan 218
Berlin 196
Padova 191
Los Angeles 186
Frankfurt am Main 154
Haiphong 149
Buffalo 148
Da Nang 141
Dallas 139
New York 130
Rome 129
Redondo Beach 127
Saint Petersburg 111
San Diego 106
Helsinki 100
Jinan 94
Biên Hòa 90
Medford 90
São Paulo 86
Quận Bình Thạnh 84
Shenyang 84
Ha Long 81
Dearborn 77
Lomé 73
Guangzhou 72
Hải Dương 72
Can Tho 71
Hebei 71
Bremen 68
Nanchang 68
Changsha 66
Turin 66
Nuremberg 65
Ninh Bình 62
Redmond 62
Bengaluru 61
Shanghai 59
Thái Nguyên 59
Tianjin 53
Abidjan 52
Chicago 52
Moscow 52
Munich 50
Florence 48
Des Moines 47
Jakarta 44
Phoenix 44
Zhengzhou 44
Falls Church 43
Norwalk 43
Vũng Tàu 42
Bắc Giang 40
Rio de Janeiro 40
Bắc Ninh 39
Toronto 39
Jiaxing 37
Naples 37
Lappeenranta 36
Mexico City 35
Hangzhou 34
London 33
Phủ Lý 33
Vinh 33
Amman 32
San Francisco 32
Quận Một 30
Xi'an 30
Vienna 28
Ningbo 27
Quận Phú Nhuận 27
Taizhou 27
Totale 25.848
Salva come PNG Salva come JPEG
Nome #
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study 2.820
Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis 491
Distonia faringea parossistica non dolorosa: un esordio atipico di sclerosi multipla. 461
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 258
Circadian Activity Rhythm in Early Relapsing-Remitting Multiple Sclerosis 236
Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis 228
Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure 222
The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. 219
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study 218
When 'good' is not good enough: a retrospective Rasch analysis study of the Berg Balance Scale for persons with Multiple Sclerosis 210
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 203
Assessing robustness of quantitative susceptibility-based MRI radiomic features in patients with multiple sclerosis 194
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: A prospective study 194
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 193
Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship 190
Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31 178
Multiparametric MRI dataset for susceptibility-based radiomic feature extraction and analysis 176
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 173
Dissipation of Motor Sleep Inertia and Motor Wake Inertia in Early Relapsing–Remitting Multiple Sclerosis 172
eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54 172
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 172
A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years 172
The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. 170
The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care system's preparedness 168
Sleep-related disorders and their relationship with MRI findings in multiple sclerosis 162
Development of a short version of MSQOL-54 using factor analysis and item response theory 160
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study 158
Decidere la maternità. Un ausilio per le donne con SM 156
Anxiety and depression in multiple sclerosis patients around diagnosis 154
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis 152
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 151
BREMSO: A simple score to predict early the natural course of multiple sclerosis 150
Burden and resources in caregivers of people with multiple sclerosis: A qualitative study 149
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 149
Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy 149
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 149
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis 148
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA) 147
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 146
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 145
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom 144
Beyond disease: Happiness, goals, and meanings among persons with multiple sclerosis and their caregivers 144
Sapere Migliora : informazioni sulla SM per la persona neodiagnosticata 142
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 141
Advance Care Planning in Neurodegenerative Disorders: A Scoping Review 141
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 140
Construction of a resource for advance care planning in multiple sclerosis (ConCure-SM): Results of cognitive debriefing with users 139
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry 139
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype 137
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis 136
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 136
The brief international cognitive assessment for multiple sclerosis (bicams): normative values in the Italian population. 136
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 135
Disability accrual in primary and secondary progressive multiple sclerosis 133
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience 133
Predictors of disability worsening in clinically isolated syndrome. 132
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 132
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 131
Comparative efficacy of switching to natalizumab in active multiple sclerosis 131
Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments 131
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells 131
The Italian multiple sclerosis register 131
A computational platform for MALDI-TOF mass spectrometry data: Application to serum and plasma samples 131
Women and multiple sclerosis: From gender medicine to precision medicine 129
User appraisal of a booklet for advance care planning in multiple sclerosis: a multicenter, qualitative Italian study 129
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial 129
Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. 129
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis 128
Explainable time-to-progression predictions in multiple sclerosis 128
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. 128
Home-based palliative approach for people with severe multiple sclerosis and their carers: Study protocol for a randomized controlled trial 128
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 127
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 124
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 124
The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. 124
F response in vascular and degenerative upper motor neuron lesions 124
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 123
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 123
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study 123
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study 123
Editorial: Aging in multiple sclerosis: from childhood to old age, in women and men 122
A comparison of the Brief International Cognitive Assessment for Multiple Sclerosis and a brief repeatable battery in multiple sclerosis patients. 122
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. 122
Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. 122
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium? 122
Applying multidimensional computerized adaptive testing to the MSQOL-54: a simulation study 121
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy 120
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder 120
Oral Fingolimod or Intramuscular interferon for relapsing multiple sclerosis 119
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS 117
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 117
Fingolimod after natalizumab and the risk of short-term relapse 116
A comparison of the brief International cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. 116
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories 116
Risk of secondary progressive multiple sclerosis: A longitudinal study 116
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. 115
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 115
IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors 114
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 114
Cognitive dysfunction in patients with relapsing-remitting Multiple Sclerosis 113
Totale 17.943
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.116
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.116
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.586 0 346 207 196 447 237 117 371 146 217 515 787
2022/20233.043 356 453 151 393 138 159 165 164 499 170 219 176
2023/20241.122 90 154 85 85 98 100 63 112 55 67 94 119
2024/20255.903 205 1.059 612 449 783 397 354 165 152 165 310 1.252
2025/202616.317 3.410 1.515 1.587 1.187 1.134 669 1.311 612 2.301 1.013 977 601
2026/20271.503 509 994 0 0 0 0 0 0 0 0 0 0
Totale 41.952